Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Otsuka_Pharmaceutical
|
| gptkbp:acquisitionYear |
2013
|
| gptkbp:collaboratedWith |
gptkb:AstraZeneca
gptkb:Janssen_Biotech gptkb:Novartis GlaxoSmithKline |
| gptkbp:focus |
oncology
central nervous system disorders |
| gptkbp:founded |
1999
|
| gptkbp:founder |
gptkb:Tom_Blundell
gptkb:Chris_Abell Harren Jhoti |
| gptkbp:headquarters_location |
gptkb:Cambridge,_United_Kingdom
|
| https://www.w3.org/2000/01/rdf-schema#label |
Astex Pharmaceuticals
|
| gptkbp:industry |
gptkb:biotechnology
pharmaceuticals |
| gptkbp:listedOn |
gptkb:NASDAQ
|
| gptkbp:parentCompany |
gptkb:Otsuka_Pharmaceutical
|
| gptkbp:product |
gptkb:SGI-110
Guadecitabine |
| gptkbp:stockSymbol |
ASTX
|
| gptkbp:technology |
fragment-based drug discovery
|
| gptkbp:website |
https://www.astx.com/
|
| gptkbp:bfsParent |
gptkb:AT7519
gptkb:SGI-110 |
| gptkbp:bfsLayer |
7
|